Trial Profile
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2020
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms ReNew
- Sponsors Aldeyra Therapeutics
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 Mar 2020 According to an Aldeyra media release, Subsequent Development Plans for Reproxalap in Dry Eye Disease Pending FDA Feedback, Expected in the Second Half of 2020.
- 24 Feb 2020 According to an Aldeyra Therapeutics media release, the company will present combined data analyses from Part 1 of the this trial and phase 2b trial.